Overview

Bioequivalence Study of CJ-30060 in Healthy Volunteers

Status:
Unknown status
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
CJ HealthCare Corporation
HK inno.N Corporation
Treatments:
Amlodipine, Valsartan Drug Combination
Rosuvastatin Calcium